- Investing.com
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company’s lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.
Metrics to compare | PTNTD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPTNTDPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.3x | −3.0x | −0.6x | |
PEG Ratio | −0.01 | 0.01 | 0.00 | |
Price/Book | −1.0x | 2.3x | 2.6x | |
Price / LTM Sales | 19.1x | 8.2x | 3.3x | |
Upside (Analyst Target) | - | 123.3% | 37.4% | |
Fair Value Upside | Unlock | 12.5% | 4.5% | Unlock |